Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $15.1 million.

  • Integra Lifesciences Holdings' Net Cash Flow rose 29260.16% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 11281.03%. This contributed to the annual value of -$23.6 million for FY2024, which is 8720.43% up from last year.
  • Integra Lifesciences Holdings' Net Cash Flow amounted to $15.1 million in Q3 2025, which was up 29260.16% from -$33.9 million recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Net Cash Flow registered a high of $320.5 million during Q1 2024, and its lowest value of -$375.5 million during Q2 2024.
  • For the 5-year period, Integra Lifesciences Holdings' Net Cash Flow averaged around -$12.2 million, with its median value being -$7.8 million (2024).
  • Within the past 5 years, the most significant YoY rise in Integra Lifesciences Holdings' Net Cash Flow was 83274.35% (2024), while the steepest drop was 1852713.44% (2024).
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Net Cash Flow stood at $42.3 million in 2021, then tumbled by 258.78% to -$67.2 million in 2022, then soared by 92.01% to -$5.4 million in 2023, then surged by 832.74% to $39.3 million in 2024, then tumbled by 61.69% to $15.1 million in 2025.
  • Its Net Cash Flow stands at $15.1 million for Q3 2025, versus -$33.9 million for Q2 2025 and -$11.8 million for Q1 2025.